Skip to main content

Haigh Adrian's Form 4 filing

Fennec Pharmaceuticals Inc. (FENC) · filed Apr 22, 2024

Accession no.
0001415889-24-011336
Filed
Apr 22, 2024
Trade date
Apr 19-22, 2024
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $414.7K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Haigh AdrianCIK 0001717425Officer (CHIEF OPERATING OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 19, 2024Common SharesMOption exerciseAcquired+22,222$2.31+$51,332.8222,222Direct
Apr 19, 2024Common SharesSSaleDisposed−22,222$9.34−$207,553.480Direct
Apr 22, 2024Common SharesMOption exerciseAcquired+22,223$2.31+$51,335.1322,223Direct
Apr 22, 2024Common SharesSSaleDisposed−22,223$9.32−$207,118.360Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 19, 2024Common SharesMOption exerciseDisposed−22,222$2.31−$51,332.82382,469Direct
Apr 22, 2024Common SharesMOption exerciseDisposed−22,223$2.31−$51,335.13360,246Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)